변비 치료 시장 : 제품 유형별, 질병 유형별, 처방 유형별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2023-2032년)

According to a new report published by Allied Market Research, titled, "Constipation Treatment Market," The constipation treatment market was valued at $5.9 billion in 2022, and is estimated to reach $10.1 billion by 2032, growing at a CAGR of 5.6% from 2023 to 2032.

The constipation treatment market growth is driven by high presence of market players who manufacture constipation treatment products, rise in prevalence of constipation, and increase in use of opioids for pain management. The well-known side effects of opioids are their impact on the gastrointestinal system, often causing constipation. This effect occurs due to the way opioids interact with receptors in the gastrointestinal tract and the nervous system. Thus, rise in population suffering from chronic pain is anticipated to drive the use of pain killers. Therefore, this factor is anticipated to increase in prevalence of constipation and boost the growth of market. For instance, according to U.S. Chronic Pain Foundation, in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. More than half (52%) said their average pain level is 7 or more on a scale of 1-10.

Moreover, rising incidence of constipation, often linked to sedentary lifestyles, poor dietary habits, and stress, is a primary driver for the growth of the constipation treatment market. Changes in dietary habits, including a shift toward processed foods with lower fiber content, can contribute to constipation. This drives the demand for treatments to alleviate its symptoms. In addition, stress and mental health issues can impact digestive processes, including bowel movements. Thus, unhealthy lifestyle factors are anticipated to increase in prevalence of constipation and drive the growth of market.

In addition, rise in number of geriatric populations is anticipated to drive the growth of the constipation treatment market. As people age, the digestive system tends to slow down, including the movement of food and waste through the intestines. This slower transit time can lead to the accumulation of stool in the colon and contribute to constipation. Thus, rise in number of geriatric populations is anticipated to increase in prevalence of constipation. For instance, according to World Health Organization (WHO), it was estimated that, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Moreover, according to Frontiers in Public Health, in 2022, it was reported that, the prevalence of constipation was 17.60% in elderly people aged 65 years and old.

The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global constipation treatment market are Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their constipation treatment market share.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the constipation treatment market analysis from 2022 to 2032 to identify the prevailing constipation treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the constipation treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global constipation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Product Benchmarking / Product specification and applications
• Upcoming/New Entrant by Regions
• New Product Development/ Product Matrix of Key Players
• Patient/epidemiology data at country, region, global level
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Product Type

• Others
• Mu-Opioid Receptor Antagonists
• Laxative
• Chloride Channel-2 Activator
• Guanylate Cyclase-C (GC-C) Agonist

By Disease Type

• Opioid-Induced Constipation
• Chronic Idiopathic Constipation
• Irritable Bowel Syndrome with Constipation

By Prescription Type

• Prescribed Drugs
• Over-the-Counter Drugs

By Distribution Channel

• Online Pharmacy
• Drug Store and Retail Pharmacy
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Europe
• LAMEA
  • Brazil
  • South Africa,
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• Abbott Laboratories
• Bausch Health Companies Inc.
• Bayer AG
• Ironwood Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Ltd.
• Prestige Consumer Healthcare Inc.
• Ardelyx Inc.
• Sanofi S.A.
• AstraZeneca plc
• AbbVie Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in prevalence of chronic pain
    • 3.4.1.2. Increase in prevalence of constipation.
    • 3.4.1.3. Rise in availability of effective drugs for constipation treatment

• 3.4.2. Restraints
  • 3.4.2.1. Side effects associated with drugs.
  • 3.4.2.2. Substitutional options available for idiopathic constipation.

• 3.4.3. Opportunities
  • 3.4.3.1. Rise in number of adoptions of key strategies by market.

CHAPTER 4: CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Mu-Opioid Receptor Antagonists
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Laxative
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Chloride Channel-2 Activator
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Guanylate Cyclase-C (GC-C) Agonist
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Others
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Opioid-Induced Constipation
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Chronic Idiopathic Constipation
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Irritable Bowel Syndrome with Constipation
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Prescribed Drugs
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Over-the-Counter Drugs
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 7.1. Overview
  • 7.1.1. Market size and forecast
• 7.2. Online Pharmacy
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by region
  • 7.2.3. Market share analysis by country
• 7.3. Drug Store and Retail Pharmacy
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by region
  • 7.3.3. Market share analysis by country
• 7.4. Others
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by region
  • 7.4.3. Market share analysis by country

CHAPTER 8: CONSTIPATION TREATMENT MARKET, BY REGION

• 8.1. Overview
  • 8.1.1. Market size and forecast By Region
• 8.2. North America
  • 8.2.1. Key market trends, growth factors and opportunities
  • 8.2.2. Market size and forecast, by Product Type
  • 8.2.3. Market size and forecast, by Disease Type
  • 8.2.4. Market size and forecast, by Prescription Type
  • 8.2.5. Market size and forecast, by Distribution Channel
  • 8.2.6. Market size and forecast, by country
    • 8.2.6.1. U.S.
    • 8.2.6.1.1. Market size and forecast, by Product Type
    • 8.2.6.1.2. Market size and forecast, by Disease Type
    • 8.2.6.1.3. Market size and forecast, by Prescription Type
    • 8.2.6.1.4. Market size and forecast, by Distribution Channel
    • 8.2.6.2. Canada
    • 8.2.6.2.1. Market size and forecast, by Product Type
    • 8.2.6.2.2. Market size and forecast, by Disease Type
    • 8.2.6.2.3. Market size and forecast, by Prescription Type
    • 8.2.6.2.4. Market size and forecast, by Distribution Channel
    • 8.2.6.3. Mexico
    • 8.2.6.3.1. Market size and forecast, by Product Type
    • 8.2.6.3.2. Market size and forecast, by Disease Type
    • 8.2.6.3.3. Market size and forecast, by Prescription Type
    • 8.2.6.3.4. Market size and forecast, by Distribution Channel
• 8.3. Europe
  • 8.3.1. Key market trends, growth factors and opportunities
  • 8.3.2. Market size and forecast, by Product Type
  • 8.3.3. Market size and forecast, by Disease Type
  • 8.3.4. Market size and forecast, by Prescription Type
  • 8.3.5. Market size and forecast, by Distribution Channel
  • 8.3.6. Market size and forecast, by country
    • 8.3.6.1. Germany
    • 8.3.6.1.1. Market size and forecast, by Product Type
    • 8.3.6.1.2. Market size and forecast, by Disease Type
    • 8.3.6.1.3. Market size and forecast, by Prescription Type
    • 8.3.6.1.4. Market size and forecast, by Distribution Channel
    • 8.3.6.2. France
    • 8.3.6.2.1. Market size and forecast, by Product Type
    • 8.3.6.2.2. Market size and forecast, by Disease Type
    • 8.3.6.2.3. Market size and forecast, by Prescription Type
    • 8.3.6.2.4. Market size and forecast, by Distribution Channel
    • 8.3.6.3. UK
    • 8.3.6.3.1. Market size and forecast, by Product Type
    • 8.3.6.3.2. Market size and forecast, by Disease Type
    • 8.3.6.3.3. Market size and forecast, by Prescription Type
    • 8.3.6.3.4. Market size and forecast, by Distribution Channel
    • 8.3.6.4. Italy
    • 8.3.6.4.1. Market size and forecast, by Product Type
    • 8.3.6.4.2. Market size and forecast, by Disease Type
    • 8.3.6.4.3. Market size and forecast, by Prescription Type
    • 8.3.6.4.4. Market size and forecast, by Distribution Channel
    • 8.3.6.5. Spain
    • 8.3.6.5.1. Market size and forecast, by Product Type
    • 8.3.6.5.2. Market size and forecast, by Disease Type
    • 8.3.6.5.3. Market size and forecast, by Prescription Type
    • 8.3.6.5.4. Market size and forecast, by Distribution Channel
    • 8.3.6.6. Rest of Europe
    • 8.3.6.6.1. Market size and forecast, by Product Type
    • 8.3.6.6.2. Market size and forecast, by Disease Type
    • 8.3.6.6.3. Market size and forecast, by Prescription Type
    • 8.3.6.6.4. Market size and forecast, by Distribution Channel
• 8.4. Asia-Pacific
  • 8.4.1. Key market trends, growth factors and opportunities
  • 8.4.2. Market size and forecast, by Product Type
  • 8.4.3. Market size and forecast, by Disease Type
  • 8.4.4. Market size and forecast, by Prescription Type
  • 8.4.5. Market size and forecast, by Distribution Channel
  • 8.4.6. Market size and forecast, by country
    • 8.4.6.1. Japan
    • 8.4.6.1.1. Market size and forecast, by Product Type
    • 8.4.6.1.2. Market size and forecast, by Disease Type
    • 8.4.6.1.3. Market size and forecast, by Prescription Type
    • 8.4.6.1.4. Market size and forecast, by Distribution Channel
    • 8.4.6.2. China
    • 8.4.6.2.1. Market size and forecast, by Product Type
    • 8.4.6.2.2. Market size and forecast, by Disease Type
    • 8.4.6.2.3. Market size and forecast, by Prescription Type
    • 8.4.6.2.4. Market size and forecast, by Distribution Channel
    • 8.4.6.3. India
    • 8.4.6.3.1. Market size and forecast, by Product Type
    • 8.4.6.3.2. Market size and forecast, by Disease Type
    • 8.4.6.3.3. Market size and forecast, by Prescription Type
    • 8.4.6.3.4. Market size and forecast, by Distribution Channel
    • 8.4.6.4. Australia
    • 8.4.6.4.1. Market size and forecast, by Product Type
    • 8.4.6.4.2. Market size and forecast, by Disease Type
    • 8.4.6.4.3. Market size and forecast, by Prescription Type
    • 8.4.6.4.4. Market size and forecast, by Distribution Channel
    • 8.4.6.5. South Korea
    • 8.4.6.5.1. Market size and forecast, by Product Type
    • 8.4.6.5.2. Market size and forecast, by Disease Type
    • 8.4.6.5.3. Market size and forecast, by Prescription Type
    • 8.4.6.5.4. Market size and forecast, by Distribution Channel
    • 8.4.6.6. Rest of Europe
    • 8.4.6.6.1. Market size and forecast, by Product Type
    • 8.4.6.6.2. Market size and forecast, by Disease Type
    • 8.4.6.6.3. Market size and forecast, by Prescription Type
    • 8.4.6.6.4. Market size and forecast, by Distribution Channel
• 8.5. LAMEA
  • 8.5.1. Key market trends, growth factors and opportunities
  • 8.5.2. Market size and forecast, by Product Type
  • 8.5.3. Market size and forecast, by Disease Type
  • 8.5.4. Market size and forecast, by Prescription Type
  • 8.5.5. Market size and forecast, by Distribution Channel
  • 8.5.6. Market size and forecast, by country
    • 8.5.6.1. Brazil
    • 8.5.6.1.1. Market size and forecast, by Product Type
    • 8.5.6.1.2. Market size and forecast, by Disease Type
    • 8.5.6.1.3. Market size and forecast, by Prescription Type
    • 8.5.6.1.4. Market size and forecast, by Distribution Channel
    • 8.5.6.2. South Africa,
    • 8.5.6.2.1. Market size and forecast, by Product Type
    • 8.5.6.2.2. Market size and forecast, by Disease Type
    • 8.5.6.2.3. Market size and forecast, by Prescription Type
    • 8.5.6.2.4. Market size and forecast, by Distribution Channel
    • 8.5.6.3. Saudi Arabia
    • 8.5.6.3.1. Market size and forecast, by Product Type
    • 8.5.6.3.2. Market size and forecast, by Disease Type
    • 8.5.6.3.3. Market size and forecast, by Prescription Type
    • 8.5.6.3.4. Market size and forecast, by Distribution Channel
    • 8.5.6.4. Rest of LAMEA
    • 8.5.6.4.1. Market size and forecast, by Product Type
    • 8.5.6.4.2. Market size and forecast, by Disease Type
    • 8.5.6.4.3. Market size and forecast, by Prescription Type
    • 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top winning strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

• 10.1. Takeda Pharmaceutical Company Ltd.
  • 10.1.1. Company overview
  • 10.1.2. Key Executives
  • 10.1.3. Company snapshot
  • 10.1.4. Operating business segments
  • 10.1.5. Product portfolio
  • 10.1.6. Business performance
• 10.2. AbbVie Inc.
  • 10.2.1. Company overview
  • 10.2.2. Key Executives
  • 10.2.3. Company snapshot
  • 10.2.4. Operating business segments
  • 10.2.5. Product portfolio
  • 10.2.6. Business performance
  • 10.2.7. Key strategic moves and developments
• 10.3. Abbott Laboratories
  • 10.3.1. Company overview
  • 10.3.2. Key Executives
  • 10.3.3. Company snapshot
  • 10.3.4. Operating business segments
  • 10.3.5. Product portfolio
  • 10.3.6. Business performance
• 10.4. Sanofi S.A.
  • 10.4.1. Company overview
  • 10.4.2. Key Executives
  • 10.4.3. Company snapshot
  • 10.4.4. Operating business segments
  • 10.4.5. Product portfolio
  • 10.4.6. Business performance
• 10.5. Bausch Health Companies Inc.
  • 10.5.1. Company overview
  • 10.5.2. Key Executives
  • 10.5.3. Company snapshot
  • 10.5.4. Operating business segments
  • 10.5.5. Product portfolio
  • 10.5.6. Business performance
  • 10.5.7. Key strategic moves and developments
• 10.6. Bayer AG
  • 10.6.1. Company overview
  • 10.6.2. Key Executives
  • 10.6.3. Company snapshot
  • 10.6.4. Operating business segments
  • 10.6.5. Product portfolio
  • 10.6.6. Business performance
• 10.7. AstraZeneca plc
  • 10.7.1. Company overview
  • 10.7.2. Key Executives
  • 10.7.3. Company snapshot
  • 10.7.4. Operating business segments
  • 10.7.5. Product portfolio
  • 10.7.6. Business performance
• 10.8. Ironwood Pharmaceuticals, Inc.
  • 10.8.1. Company overview
  • 10.8.2. Key Executives
  • 10.8.3. Company snapshot
  • 10.8.4. Operating business segments
  • 10.8.5. Product portfolio
  • 10.8.6. Business performance
  • 10.8.7. Key strategic moves and developments
• 10.9. Prestige Consumer Healthcare Inc.
  • 10.9.1. Company overview
  • 10.9.2. Key Executives
  • 10.9.3. Company snapshot
  • 10.9.4. Operating business segments
  • 10.9.5. Product portfolio
  • 10.9.6. Business performance
• 10.10. Ardelyx Inc.
  • 10.10.1. Company overview
  • 10.10.2. Key Executives
  • 10.10.3. Company snapshot
  • 10.10.4. Operating business segments
  • 10.10.5. Product portfolio
  • 10.10.6. Key strategic moves and developments